Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor α and γ dual agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 20, 2008, Pages 6318-6333

  Suh, Young Ger ^a   Kim, Nam Jung ^a   Koo, Bon Woong ^a   Lee, Kwang Ok ^a   Moon, Sung Hyun ^a   Shin, Dong Hyung ^a   Jung, Jong Wha ^a   Paek, Seung Mann ^a   Chang, Dong Jo ^a   Li, Funan ^a   Kang, Hyun Jin ^b   Le, Tuong Vy Thi ^b   Yu, Na Chae ^c   Chang, Yell Shin ^c   Kim, Mi Kyung ^c   Joong, In Lim ^c   Ryu, Jae Sang ^d   Park, Hyun Ju ^b  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Dong A Pharmaceutical Company   (South Korea)

^d Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [1 (4 CHLOROBENZYLOXYIMINO)ETHYL]PHENYL] 2 ETHOXYPROPANOIC ACID; 3 [3 [1 (FLUOROBENZYLOXYIMINO)ETHYL]PHENYL] 2 ETHOXYPROPANOIC ACID; GEMFIBROZIL; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLPROPANOIC ACID DERIVATIVE; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; TESAGLITAZAR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; GLUCOSE METABOLISM; LIPID METABOLISM; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; WEIGHT GAIN;

ANIMALS; CELL LINE; DRUG DESIGN; HUMANS; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS);

EID: 54549120494     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8003416     Document Type: Article

References (34)

1. (a) Willson, T. M.; Brown, P. J.; Stembach, D. D.; Henke, B. R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 2000, 43, 527-550.
2. (b) Savage, D. B. PPARγ as a metabolic regulator: insights from genomics and pharmacology. Expert. Rev. Mol. Med. 2005, 7, 1-16.
3. (c) Evans, R. M.; Barish, G. D.; Wang, Y. X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10, 355-361.
4. (d) Kota, B. P.; Huang, T. H.; Roufogalis, B. D. An overview on biological mechanisms of PPARs. Pharmacol. Res. 2005, 51, 85-94.
5. (e) Berger, J. P.; Akiyama, T. E.; Meinke, P. T. PPARs: therapeutic targets for metabolic disease. Trends. Pharmacol. Sci. 2005, 26, 244-251.
6. (a) Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wassermann, K.; Brand, C. L.; Sturis, J.; Wöldike, H. F.; Fleckner, J.; Andersen, A. S.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPAR α/γ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 2002, 45, 789-804.
7. (b) Devasthale, P. V.; Chen, S.; Jeon, Y.; Qu, F.; Shao, C.; Wang, W.; Zhang, H.; Cap, M.; Farrelly, D.; Golla, R.; Grover, G.; Harrity, T.; Ma, Z.; Moore, L.; Ren, J.; Seethala, R.; Cheng, L.; Sleph, P.; Sun, W.; Tieman, A.; Wetterau, J. R.; Doweyko, A.; Chandrasena, G.; Chang, S. Y.; Humphreys, W. G.; Sasseville, V. G.; Biller, S. A.; Ryono, D. E.; Selan, F.; Hariharan, N.; Cheng, P. T. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities. J. Med. Chem. 2005, 48, 2248-2250.
8. (c) Liu, K.; Xu, L.; Berger, J. P.; Macnaul, K. L.; Zhou, G.; Doebber, T. W.; Forrest, M. J.; Moller, D. E.; Jones, A. B. Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia. J. Med. Chem. 2005, 48, 2262-2265.
9. (d) Cai, Z.; Feng, J.; Guo, Y.; Li, P.; Shen, Z.; Chu, F.; Guo, Z. Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARα/γ agonists. Bioorg. Med. Chem. 2006, 14, 866-874.
10. (e) Kim, N. J.; Lee, K. O.; Koo, B. W.; Li, F.; Yoo, J. K.; Park, H. J.; Min, K. H.; Lim, J. I.; Kim, M. K.; Kim, J. K.; Suh, Y. G. Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists. Bioorg. Med. Chem. Lett. 2007, 17, 3595-3598.
11. (a) Galida-Dual PPAR Agonist for Type 2 Diabetes and Metabolic Syndrome. http://www.drugdevelopment-technology.com.
12. (b) Nissen, S. E.; Wolski, K.; Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. J. Am. Med. Assoc. 2005, 294, 2581-2586.
13. (a) Egerod, F. L.; Nielsen, H. S.; Iversen, L.; Thorup, I.; Storgaard, T.; Oleksiewicz, M. B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 2005, 10, 295-309.
14. (b) Oleksiewicz, M. B.; Thorup, I.; Nielsen, H. S.; Andersen, H. V.; Hegelund, A. C.; Iversen, L.; Guldberg, T. S.; Brinck, P. R.; Sjogren, I.; Thinggaard, U. K.; Jørgensen, L.; Jensen, M. B. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol. Pathol. 2005, 33, 552-560.
15. (c) Cohen, S. M. Effects of PPARγ and combined agonists on the urinary tract of rats and other species. Toxicol. Sci. 2005, 87, 322-327.
16. Schuster, H.; Fagerberg, B.; Edwards, S.; Halmos, T.; Lopatynski, J.; Stender, S.; Birketvedt, G. S.; Tonstad, S.; Gause-Nilsson, I.; Halldórsdóttir, S.; Ohman, K. P. SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, improves apolipoprotein levels in nondiabetic subjects with insulin resistance. Atherosclerosis 2008, 197, 355-362.
17. Wilding, J. P.; Gause-Nilsson, I.; Persson, A. GALLANT 7 Study Group. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diabetes Vasc. Dis. Res. 2007, 4, 194-203.
18. Keech, A.; Simes, R. J.; Barter, P.; Best, J.; Scott, R.; Taskinen, M. R.; Forder, P.; Pillai, A.; Davis, T.; Glasziou, P.; Drury, P.; Kesäniemi, Y. A.; Sullivan, D.; Hunt, D.; Colman, P.; d'Emden, M.; Whiting, M.; Ehnholm, C.; Laakso, M. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 2005, 366, 1849-1861.
19. (a) Lebovitz, H. E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab. Res. Rev. 2002, 18 (Suppl. 2), S23-S29.
20. (b) Karalliedde, J.; Buckingham, R. E. Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies. Drug Saf. 2007, 30, 741-753.
21. (a) Carmona, M. C.; Louche, K.; Nibbelink, M.; Prunet, B.; Bross, A.; Desbazeille, M.; Dacquet, C.; Renard, P.; Casteilla, L.; Pénicaud, L. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int. J. Obes. (London) 2005, 29, 864-871.
22. (b) Fiévet, C.; Fruchart, J. C.; Staels, B. PPAR α and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 2006, 6, 606-614.
23. Kuhn, B.; Hilpert, H.; Benz, J.; Binggeli, A.; Grether, U.; Humm, R.; Märki, H. P.; Meyer, M.; Mohr, P. Structure-based design of indole propionic acids as novel PPAR α/γ co-agonists. Bioorg. Med. Chem. Lett. 2006, 16, 4016-4020.
24. Cronet, P.; Petersen, J. F.; Folmer, R.; Blomberg, N.; Sjöblom, K.; Karlsson, U.; Lindstedt, E. L.; Bamberg, K. Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family. Structure 2001, 9, 699-706.
25. (a) Matsuura, F.; Emori, E.; Shinoda, M.; Clark, R.; Sakai, S.; Yoshitomi, H.; Yamazaki, K.; Inoue, T.; Miyashita, S.; Hihara, T.; Harada, H.; Ohashi, K. Carboxylic acid derivative and salt thereof. U.S. Patent US20040102634, 2004.
26. (b) Han, H. O.; Koh, J. S.; Kim, G. T.; Kim, S. H.; Kim, K.-H.; Chung, H.-K.; Lee, H. M.; Park, O. K.; Woo, S. H.; Yim, H. J.; Hur, G.-C.; Kim, H. J.; Koo, K. D.; Lee, C.-S.; Hong, S. W.; Kim, S. H. Novel compounds as agonist for PPARγ and PPARα, Method for preparation of the same, and pharmaceutical composition containing the same. Patent WO 2006057503, 2006.
27. (c) Wang, W.; Devasthale, P.; Farrelly, D.; Gu, L.; Harrity, T.; Cap, M.; Chu, C.; Kunselman, L.; Morgan, N.; Ponticiello, R.; Zebo, R.; Zhang, L.; Locke, K.; Lippy, J.; O'Malley, K.; Hosagrahara, V.; Zhang, L.; Kadiyala, P.; Chang, C.; Muckelbauer, J.; Doweyko, A. M.; Zahler, R.; Ryono, D.; Hariharan, N.; Cheng, P. T. Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists. Bioorg. Med. Chem. Lett. 2008, 18, 1939-1944.
28. SYBYL Molecular Modeling System [7.0]; Tripos Inc.: St. Louis, MO, 2004.
29. Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H. J.; Frost Jensen, A.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor α/γ agonist ragaglitazar. J. Med. Chem. 2003, 46, 1306-1317.
30. Hawthorne, M. F.; Emmons, W. D.; McCallum, K. S. A re-examination of the peroxyacid cleavage of ketones. I. Relative migratory aptitudes. J. Am. Chem. Soc. 1958, 80, 6393-6398.
31. Mitsunobu, O.; Yamada, M.; Mukaiyama, T. Preparation of esters of phosphoric acid by the reaction of trivalent phosphorus compounds with diethyl azodicarboxylate in the presence of alcohols. Bull. Chem. Soc. Jpn. 1967, 40, 935-939.
32. Paek, S.-M.; Seo, S.-Y.; Kim, S.-H.; Jung, J.-W.; Lee. Y.-S.; Jung, J.-K.; Suh, Y.-G. Concise Syntheses of (+)-Macrosphelides A and B. Org. Lett. 2005, 7, 3159-3162.
33. Baraldi, P. G.; Barco, A.; Benetti, S.; Manfredini, S.; Simoni, D. Ring Cleavage of 3,5-Disubstituted 2-Isoxazolines by Molybdenum Hexacarbonyl and Water to β-Hydroxy Ketones. Synthesis 1987, 1987, 276-278.
34. Mittra, S.; Sangle, G.; Tandon, R.; Sharma, S.; Roy, S.; Khanna, V.; Gupta, A.; Sattigeri, J.; Sharma, L.; Priyadarsiny, P.; Khattar, S. K.; Bora, R. S.; Saini, K. S.; Bansal, V. S. Increase in weight induced by muraglitazar, a dual PPARα/γ agonist, in db/db mice: adipogenesis/or edema. Br. J. Pharmacol. 2007, 150, 480-487.